Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 17, 2026Open Access

Advanced Oral Drug Delivery Platforms for Type 2 Diabetes Mellitus: Bridging Pharmacokinetic Challenges and Glycaemic Outcomes

View Full Paper
Ask AI
Bookmark
Share

Authors

BMBidgar Saraswati M.*TBTambade Yogesh B.KDKolekar Mahesh D.

Discussion

Loading...

Member takes

Overview

Review examines challenges in drug delivery for Type 2 diabetes and evaluates advanced platforms for improved outcomes.

Key Points

  • This review aims to explore the challenges in drug delivery for Type 2 diabetes and evaluate advanced oral delivery platforms.
  • Analyzed gastrointestinal physiological challenges affecting drug absorption in Type 2 diabetes.
  • Critically reviewed gastroretentive systems, nanocarrier platforms, and next-generation drug delivery concepts.
  • Evaluated various frameworks, including Quality by Design and physiologically based pharmacokinetic modeling.
  • Gastroretentive systems demonstrated up to 3.17-fold improvements in bioavailability for narrow absorption window antidiabetics.
  • Nanocarrier platforms, including PLGA nanoparticles and chitosan-coated nanoemulsions, was assessed against BCS selection logic.
  • Identified the need to match delivery platforms to the pharmacokinetic barriers of each drug class.

Cite This Study

M.* et al. (2026) studied this question.

synapsesocial.com/papers/6a323d57d50b63ecad207108https://doi.org/10.5281/zenodo.20702820
View Full Paper
Ask AI
Bookmark
Share